Blueprint Medicines Corporation (BPMC)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.01 (-0.01%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Blueprint Medicines Corporation (BPMC)
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Key Insights

Critical company metrics and information

  • Share Price

    $96.52

  • Market Cap

    $6.13 Billion

  • Total Outstanding Shares

    63.53 Million Shares

  • Total Employees

    655

  • Dividend

    No dividend

  • IPO Date

    April 30, 2015

  • SIC Description

    Pharmaceutical Preparations

  • Homepage

    https://www.blueprintmedicines.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities$-242.15 Million
Net Cash Flow From Financing Activities$278.88 Million
Net Cash Flow$34.29 Million
Net Cash Flow From Financing Activities, Continuing$278.88 Million
Net Cash Flow, Continuing$34.29 Million
Net Cash Flow From Investing Activities, Continuing$-2.44 Million
Net Cash Flow From Investing Activities$-2.44 Million
Net Cash Flow From Operating Activities, Continuing$-242.15 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations Before Tax$-127.43 Million
Basic Average Shares$62.72 Million
Gross Profit$421.44 Million
Selling, General, and Administrative Expenses$342.14 Million
Operating Expenses$697.39 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Operating Income/Loss$-275.95 Million
Benefits Costs and Expenses$561.85 Million
Income/Loss From Continuing Operations After Tax$-128.05 Million
Cost Of Revenue$12.98 Million
Revenues$434.42 Million
Income Tax Expense/Benefit$615000.00
Diluted Earnings Per Share$2.09
Nonoperating Income/Loss$148.52 Million
Research and Development$355.30 Million
Preferred Stock Dividends And Other Adjustments$0.00
Diluted Average Shares$62.72 Million
Net Income/Loss$-128.05 Million
Basic Earnings Per Share$2.09
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Net Income/Loss Available To Common Stockholders, Basic$-128.05 Million
Costs And Expenses$710.37 Million
Net Income/Loss Attributable To Parent$-128.05 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Liabilities$886.50 Million
Fixed Assets$37.85 Million
Accounts Payable$4.72 Million
Wages$40.27 Million
Assets$1.20 Billion
Other Non-current Assets$306.95 Million
Noncurrent Liabilities$628.84 Million
Liabilities And Equity$1.20 Billion
Current Liabilities$257.66 Million
Equity Attributable To Noncontrolling Interest$0.00
Other Current Assets$842.32 Million
Inventory$12.53 Million
Current Assets$854.85 Million
Noncurrent Assets$344.80 Million
Other Current Liabilities$212.68 Million
Equity$313.15 Million
Equity Attributable To Parent$313.15 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.